Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI113247

Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients.

C Boitard, G Feutren, L Castano, M Debray-Sachs, R Assan, J Hors, and J F Bach

Institut National de la Santé et de la Recherche Médicale (INSERM) U 25, Hôpital Necker, Paris, France.

Find articles by Boitard, C. in: PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U 25, Hôpital Necker, Paris, France.

Find articles by Feutren, G. in: PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U 25, Hôpital Necker, Paris, France.

Find articles by Castano, L. in: PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U 25, Hôpital Necker, Paris, France.

Find articles by Debray-Sachs, M. in: PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U 25, Hôpital Necker, Paris, France.

Find articles by Assan, R. in: PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U 25, Hôpital Necker, Paris, France.

Find articles by Hors, J. in: PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U 25, Hôpital Necker, Paris, France.

Find articles by Bach, J. in: PubMed | Google Scholar

Published December 1, 1987 - More info

Published in Volume 80, Issue 6 on December 1, 1987
J Clin Invest. 1987;80(6):1607–1612. https://doi.org/10.1172/JCI113247.
© 1987 The American Society for Clinical Investigation
Published December 1, 1987 - Version history
View PDF
Abstract

Anti-islet cell and anti-insulin antibody production was studies over a 12-mo period in 82 recently diagnosed diabetics randomly receiving either cyclosporin or placebo. Cyclosporin had only minimal effects on the production of anti-islet cell antibodies whether directed to islet cytoplasmic (immunofluorescence) or membrane (cytotoxicity assay) antigens even in patients undergoing remission. These data suggest that these antibodies do not play a major role in the pathogenesis of the disease particularly since their (irregular) presence is not predictive of the clinical response to cyclosporin. Conversely, cyclosporin completely suppressed the synthesis of antibodies elicited by exogenous insulin irrespective of the insulin doses received, and decreased the autoantibody production against thyroid antigens, indicating that cyclosporin has variable effects on antibody production against various antigens.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1607
page 1607
icon of scanned page 1608
page 1608
icon of scanned page 1609
page 1609
icon of scanned page 1610
page 1610
icon of scanned page 1611
page 1611
icon of scanned page 1612
page 1612
Version history
  • Version 1 (December 1, 1987): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts